Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543101 · ClinicalTrials.gov registry record · Phase 4
Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors
A Phase 4 study, sponsored by Community Research Initiative of New England.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT00543101: Completed Phase 4 study, sponsored by Community Research Initiative of New England.
NCT00543101 is a Phase 4 study that has completed, run by Community Research Initiative of New England. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00543101, a Phase 4 study, has completed, sponsored by Community Research Initiative of New England.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will evaluate patients who have achieved virologic suppression (\< 400 copies/mL) on any dual protease inhibitor (PI) combination, to determine whether patients can substitute both PIs with the single boosted PI darunavir given 600/100 ritonavir (RTV) twice daily (BID) and maintain comparable virologic suppression (% \< 50 c/mL) for 24 weeks.
Interventions
- DRUG Darunavir (DRV/r)
- DRUG continue on current dual boosted PI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00543101
The ClinicalTrials.gov registry entry for NCT00543101 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Community Research Initiative of New England, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Darunavir (DRV/r) is the first listed.
NCT00543101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00543101 about?
NCT00543101 is a clinical study titled "Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors". This study will evaluate patients who have achieved virologic suppression (\< 400 copies/mL) on any dual protease inhibitor (PI) combination, to determine whether patients can substitute both PIs with the single boosted PI darunavir given 600/100 ritonavir (RTV) twice daily (BID) and maintain compar...
What is the current status of trial NCT00543101?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2007-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00543101?
The interventions under investigation include: Darunavir (DRV/r) (DRUG), continue on current dual boosted PI (DRUG).
Who is sponsoring clinical trial NCT00543101?
This trial is sponsored by Community Research Initiative of New England, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.